Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

• Main Authors: Jun Lu (Author), Jun Wu (Author), Yuqing Lou (Author), Qin Shi (Author), Jun Xu (Author), Lele Zhang (Author), Wei Nie (Author), Jie Qian (Author), Yanan Wang (Author), Yanwei Zhang (Author), Jing Jiao (Author), Xueyan Zhang (Author), Wei Zhang (Author), Huimin Wang (Author), Tianqing Chu (Author), Hua Zhong (Author), Baohui Han (Author)
• Format: Book
• Published: BMC, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Circulating tumour DNA (ctDNA)-based sequencing might provide a simple test for the stratified model of non-small cell lung cancer (NSCLC). Here, we aimed to assess the ctDNA sequencing-based tumour mutation index (TMI) model for screening responders (from non-responders) among N...